journal
MENU ▼
Read by QxMD icon Read
search

Journal of Thrombosis and Haemostasis: JTH

journal
https://www.readbyqxmd.com/read/29125709/chronic-kidney-disease-and-bleeding-risk-in-patients-at-high-cardiovascular-risk-a-cohort-study
#1
G Ocak, M B Rookmaaker, A Algra, G J de Borst, P A Doevendans, L J Kappelle, M C Verhaar, F L Visseren
BACKGROUND: There are indications that patients with chronic kidney disease have an increased bleeding risk. OBJECTIVES: The aim of our study was to investigate the association between chronic kidney disease and bleeding in patients at high cardiovascular risk. METHODS: We included 10,347 subjects referred to the University Medical Center Utrecht (the Netherlands) from September 1996 to February 2015 for an out-patient visit with classical risk factors for arterial disease or with symptomatic arterial disease (Second Manifestation of Arterial disease (SMART) cohort)...
November 10, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29125695/age-adjusted-d-dimer-to-rule-out-deep-vein-thrombosis-findings-from-the-palladio-algorithm
#2
Nicoletta Riva, Giuseppe Camporese, Matteo Iotti, Eugenio Bucherini, Marc Righini, Pieter W Kamphuisen, Peter Verhamme, James D Douketis, Chiara Tonello, Paolo Prandoni, Walter Ageno
BACKGROUND: Age-adjusted D-dimer has been proposed to increase specificity for the diagnosis of venous thromboembolism (VTE). However, the accuracy of this threshold has been recently questioned. OBJECTIVES: To assess the diagnostic performance of age-adjusted D-dimer combined with clinical pre-test probability (PTP) in patients with suspected deep vein thrombosis (DVT). METHODS: PALLADIO (NCT01412242) was a multicentre management study that validated a new diagnostic algorithm, incorporating PTP, D-dimer (using manufacturers' cut-off), and limited or extended compression ultrasonography (CUS) in outpatients with clinically suspected DVT...
November 10, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29125690/cancer-and-risk-of-cerebral-venous-thrombosis-a-case-control-study
#3
S M Silvis, S Hiltunen, E Lindgren, K Jood, S M Zuurbier, S Middeldorp, J Putaala, S C Cannegieter, T Tatlisumak, J M Coutinho
BACKGROUND: Cancer is an established risk factor for leg vein thrombosis and pulmonary embolism. Controlled studies assessing the risk of cerebral venous thrombosis (CVT) in patients with cancer have not been performed. OBJECTIVE: To assess whether cancer is a risk factor for CVT. PATIENTS/METHODS: Case-control study. We assessed consecutive adult patients with CVT from three academic hospitals from 1987-2015, and control subjects from the Dutch MEGA study (Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis)...
November 10, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29121438/platelet-rescue-by-macrophage-depletion-in-obese-adamts13-deficient-mice-at-risk-for-thrombotic-thrombocytopenic-purpura
#4
Lotte Geys, Elien Roose, Ilse Scroyen, Hanspeter Rottensteiner, Claudia Tersteeg, Marc F Hoylaerts, Karen Vanhoorelbeke, H Roger Lijnen
BACKGROUND: Thrombotic thrombocytopenic purpura (TTP) is caused by the absence of ADAMTS13 activity. Thrombocytopenia is presumably related to the formation of microthrombi rich in von Willebrand Factor (VWF) and platelets. Obesity may be a risk factor for TTP; it is associated with abundance of macrophages that may phagocytose platelets. OBJECTIVES: To evaluate the role of obesity and ADAMTS13 deficiency in TTP, and to establish whether macrophages contribute to thrombocytopenia...
November 9, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29117459/receptor-homodimerization-plays-a-critical-role-in-a-novel-dominant-negative-p2ry12-variant-identified-in-a-family-with-severe-bleeding
#5
Stuart J Mundell, David Rabbolini, Sara Gabrielli, Qiang Chen, Riyaad Aungraheeta, James L Hutchinson, Tatjana Kilo, Joel Mackay, Christopher M Ward, William Stevenson, Marie-Christine Morel-Kopp
BACKGROUND: Although inherited platelet disorders are still underdiagnosed worldwide, advances in molecular techniques are improving disease diagnosis and patient management. OBJECTIVE: To identify and characterize the mechanism underlying the bleeding phenotype in a Caucasian family with an autosomal dominant P2RY12 variant. METHODS: Full blood count, platelet aggregometry, flow cytometry and western-blotting were performed before NGS. Detailed molecular analysis of the identified P2Y12R receptor's variant was subsequently performed in mammalian cells over-expressing receptor constructs...
November 8, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29112333/associations-of-activated-coagulation-factor-vii-and-factor-viia-antithrombin-levels-with-genome-wide-polymorphisms-and-cardiovascular-disease-risk
#6
N C Olson, L M Raffield, L A Lange, E M Lange, W T Longstreth, G Chauhan, S Debette, S Seshadri, A P Reiner, R P Tracy
BACKGROUND: A fraction of coagulation factor VII circulates as an active protease (FVIIa). FVIIa also circulates as an inactivated complex with antithrombin (FVIIa-AT). OBJECTIVE: Evaluate associations of FVIIa and FVIIa-AT with genome-wide single nucleotide polymorphisms (SNPs) and incident coronary heart disease, ischemic stroke, and mortality. PATIENTS/METHODS: We measured FVIIa and FVIIa-AT in 3,486 Cardiovascular Health Study (CHS) participants...
November 7, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29108103/adamts13-and-von-willebrand-factor-a-dynamic-duo
#7
REVIEW
Kieron South, David A Lane
VWF is a key player in haemostasis, acting as a carrier for FVIII and capturing platelets at sites of vascular damage. To capture platelets, it must undergo conformational changes, both within its A1 domain and at the macromolecular level through A2 domain unfolding. Its size and this function are regulated by the metalloproteinase, ADAMTS13. Recently, it has been shown that ADAMTS13 undergoes a conformational change upon interaction with VWF and that this enhances its activity towards its substrate. This review summarises recent work on these conformational transitions, describing how they are controlled...
November 6, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29108091/effects-of-low-dose-epinephrine-on-perioperative-hemostasis-and-inflammatory-reaction-in-major-surgeries-a%C3%A2-randomized%C3%A2-clinical-trial
#8
J L Liu, W N Zeng, F Y Wang, C Chen, X Y Gong, H Yang, Z J Tan, X L Jia, L Yang
BACKGROUND: Haemostasis, thrombosis, and surgical stress-induced immune reaction are important for perioperative morbidity and recovery in major surgeries. OBJECTIVES: This study aimed to evaluate the effects of combined administration of low-dose epinephrine (LDEPI) plus tranexamic acid (TXA) on perioperative blood loss, thromboembolic complications, and inflammatory response in total hip arthroplasty (THA). PATIENTS /METHODS: Patients scheduled for THA (n = 195) were randomized into 3 interventions: intravenous (IV) LDEPI plus TXA (Group IV); topical (TP) diluted-epinephrine plus TXA (Group TP); and TXA alone as control (CT) (Group CT)...
November 6, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29108090/characteristics-and-quality-of-oral-anticoagulation-treatment-in-pediatric-patients-in-the-netherlands-based-on-the-caps-cohort
#9
Hedy Maagdenberg, Marc B Bierings, C Heleen van Ommen, Felix J M van der Meer, Inge M Appel, Rienk Y J Tamminga, Anthonius de Boer, Anke H Maitland-van der Zee
BACKGROUND: The use of vitamin-K antagonists in pediatric patients is rare and information on quality and safety of the treatment with acenocoumarol and phenprocoumon is limited. OBJECTIVES: To assess the quality, safety and effectiveness during the first year of acenocoumarol and phenprocoumon treatment in pediatric patients in the Netherlands. METHODS: The Children Anticoagulation and Pharmacogenetics Study (CAPS) was designed as a multicenter retrospective follow-up study...
November 6, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29106076/rivaroxaban-reversal-with-prothrombin-complex-concentrate-or-tranexamic-acid-in-healthy-volunteers
#10
J H Levy, K T Moore, M D Neal, D Schneider, V S Marcsisin, J Ariyawansa, J I Weitz
BACKGROUND: Oral factor Xa inhibitors such as rivaroxaban are widely used, but specific reversal agents are lacking. Although 4-factor-prothrombin complex concentrate (4F-PCC) and tranexamic acid (TXA) are sometimes used to manage serious bleeding, their efficacy is unknown. Prior studies in healthy subjects taking rivaroxaban revealed that 4F-PCC partially reverses the prolonged prothrombin time (PT), and fully restores endogenous thrombin potential (ETP). The effect of TXA has not been evaluated...
November 6, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29094466/joint-effects-of-prothrombotic-genotypes-and-body-height-on-the-risk-of-venous-thromboembolism-the-troms%C3%A3-study
#11
Lars D Horvei, Sigrid K Braekkan, Erin N Smith, Terry Solomon, Kristian Hindberg, Kelly A Frazer, Frits R Rosendaal, John-Bjarne Hansen
BACKGROUND: Studies have reported synergistic effects of prothrombotic single nucleotide polymorphisms (SNPs) and obesity on the risk of venous thromboembolism (VTE). Tall stature is associated with increased VTE risk, but the joint effect of prothrombotic genotypes and tall stature on VTE risk is unknown. AIMS: To investigate the joint effects of prothrombotic genotypes and tall stature on the risk of VTE. METHODS: Cases with incident VTE (n=676) and a randomly selected age-weighted subcohort (n=1842) were sampled from the Tromsø study (cohort follow-up: 1994-2012)...
November 2, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29080391/timing-and-severity-of-inhibitor-development-in-recombinant-versus-plasma-derived-factor-viii-concentrates-a-sippet-analysis
#12
F Peyvandi, A Cannavò, I Garagiola, R Palla, P M Mannucci, F R Rosendaal
BACKGROUND: The development of neutralizing antibodies (inhibitors) against factor VIII (FVIII) is the most severe complication in the early phases of treatment of severe haemophilia A. Recently a randomized trial, the Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET) demonstrated a two-fold higher risk of inhibitors development in children treated with recombinant FVIII (rFVIII) products than with plasma-derived FVIII (pdFVIII) during the first 50 exposure days (EDs). OBJECTIVE/METHODS: In this post-hoc SIPPET analysis we evaluated the rate of inhibitor incidence over time by every 5 EDs (from 0 to 50 EDs) in patients treated with different classes of FVIII product, made possible by a frequent testing regime...
October 28, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29080389/sippet-insights-into-factor-viii-immunogenicity
#13
Padraic G Fallon, Michelle Lavin, James S O'Donnell
In this issue of the Journal of Thrombosis and Haemostasis, Peyvandi et al present further insights from the Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET) study regarding the relative immunogenicity of recombinant- (rFVIII) versus plasma-derived FVIII (pdFVIII) in patients with haemophilia A [1]. In a post-hoc analysis of this prospective randomised controlled trial, the timing and severity of inhibitor development for previously untreated patients (PUPs) treated with rFVIII was compared with that in PUPs treated with pdFVIII...
October 28, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29080382/factor-xiii-co-treatment-with-hemostatic-agents-in-hemophilia-a-increases-fibrin-%C3%AE-chain-crosslinking
#14
Joan D Beckman, Lori A Holle, Alisa S Wolberg
BACKGROUND: Hemophilia A results from the absence, deficiency, or inhibition of factor VIII (FVIII). Bleeding is treated with hemostatic agents (FVIII, recombinant activated factor VIIa [rFVIIa], anti-inhibitor coagulation complex [FEIBA], or recombinant porcine FVIII [rpFVIII]). Despite treatment, some patients have prolonged bleeding. Factor XIII-A2 B2 (FXIII) is a protransglutaminase. During clot contraction, thrombin-activated FXIII (FXIIIa) crosslinks fibrin and α2 -antiplasmin, which promotes red blood cell retention and increases clot stability and weight...
October 28, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29065247/international-collaborative-study-for-the-calibration-of-proposed-international-standards-for-thromboplastin-rabbit-plain-and-for-thromboplastin-recombinant-human-plain
#15
Antonius M H P van den Besselaar, Veena Chantarangkul, Franca Angeloni, Nikolaus B Binder, Mary Byrne, Raymond Dauer, Brynja R Gudmundsdottir, Jørgen Jespersen, Steven Kitchen, Cristina Legnani, Tomas L Lindahl, Richard A Manning, Marta Martinuzzo, Olga Panes, Vittorio Pengo, Anne Riddell, Sitalakshmi Subramanian, Attila Szederjesi, Chaicharoen Tantanate, Petra Herbel, Armando Tripodi
BACKGROUND: The availability of International Standards for thromboplastin is essential for the calibration of routine reagents and hence the calculation of the International Normalized Ratio (INR). Stocks of the current 4(th) International Standards are running low. Candidate replacement materials have been prepared. This report describes the calibration of the proposed 5(th) International Standards for thromboplastin, rabbit, plain (coded RBT/16) and for thromboplastin, recombinant, human, plain (coded rTF/16)...
October 24, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29065242/ageing-of-the-venous-valves-as-a-new-risk-factor-for-venous-thrombosis-in-the-elderly-the-batavia-study
#16
A Karasu, A Šrámek, F R Rosendaal, R J van der Geest, A van Hylckama Vlieg
BACKGROUND: Increasing age is the strongest risk factor for venous thrombosis (VT). Increasing age has been related to a thickening of the venous valves and a decreased valvular function. The association between valve thickness and the risk of VT is not known. OBJECTIVES: To assess the association between increased valve thickness and valve closure time (VCT) and the risk of VT. METHODS: Analyses were performed in the BATAVIA study, including 70 cases aged 70+ with a first VT and 96 controls...
October 24, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29064634/the-international-society-on-thrombosis-and-haemostasis-bleeding-assessment-tool-isth-bat-and-the-risk-of-future-bleeding
#17
Maria Rosaria Fasulo, Eugenia Biguzzi, Maria Abbattista, Francesca Stufano, Maria Teresa Pagliari, Ilaria Mancini, Marcin M Gorski, Antonino Cannavò, Matteo Corgiolu, Flora Peyvandi, Frits R Rosendaal
BACKGROUND: The International Society on Thrombosis and Haemostasis-Bleeding Assessment Tool (ISTH-BAT) is a diagnostic tool used in subjects with suspected inherited bleeding disorders for diagnostic purposes. AIM: To evaluate whether the ISTH-BAT, recorded at first work-up in a tertiary care center, predicts the risk of subsequent bleeding events METHODS: Observational cohort study including all consecutive subjects referred between 2011 and 2015 because of a suspected bleeding disorder, of any sex and age...
October 24, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29064625/coincidence
#18
EDITORIAL
F R Rosendaal, P H Reitsma
No abstract text is available yet for this article.
October 24, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29064619/external-validation-of-the-plasmic-score-a-clinical-prediction-tool-for-thrombotic-thrombocytopenic-purpura-diagnosis-and-treatment
#19
Ang Li, Parisa R Khalighi, Qian Wu, David A Garcia
BACKGROUND: The PLASMIC score was recently published to distinguish patients with severe ADAMTS-13 deficiency from those without for early identification of thrombotic thrombocytopenia purpura (TTP). OBJECTIVE: We performed an independent external validation of the PLASMIC score for clinical prediction of severe ADAMTS-13 deficiency. PATIENTS/METHODS: We studied an independent cohort of 112 consecutive hospitalized patients with suspected thrombotic microangiopathy and appropriate ADAMTS-13 testing (including 21 patients with TTP diagnosis)...
October 24, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29064615/evaluation-of-a-microfluidic-flow-assay-to-screen-for-von-willebrand-disease-and-low-von-willebrand-factor-levels
#20
Marcus Lehmann, Katrina Ashworth, Marilyn Manco-Johnson, Jorge Di Paola, Keith B Neeves, Christopher J Ng
BACKGROUND: Von Willebrand disease (VWD) is a mucocutaneous bleeding disorder with a reported prevalence of 1 in 10,000. VWF function and platelet adhesion are regulated by hemodynamic forces that are not integrated into most current clinical assays. OBJECTIVE: We evaluated whether a custom microfluidic flow assay (MFA) can screen for deficiencies in VWF in patients presenting with mucocutaneous bleeding. METHODS: Whole blood from individuals with mucocutaneous bleeding was assayed in a custom MFA...
October 24, 2017: Journal of Thrombosis and Haemostasis: JTH
journal
journal
20181
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"